BeyondSpring Inc.

NASDAQ:BYSI

Biotechnology

Healthcare
$1.25 +1.58%

+$0.03 today

Market cap
$51.40M
Beta
0.42
P/E (TTM)
-8.7
EPS (TTM)
-$0.19
52W Low $1.18High $3.28

Volume 0.01M

Average 0.02M

BYSI Net Income

Bottom-line profit, the starting point for calculating cash from operations.

BeyondSpring Inc.NASDAQ: BYSI

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income dips below year-ago levels

Q1 FY2026 net income of $2.22M (cash outflow) fell 11.6% year over year, behind the +33.3% change in trailing-twelve-month net income. Sequentially, it fell 6.5% from the prior quarter. Over 3 fiscal years it compounded at -38.4% a year.

Context

  • Net income grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 1 analysts of $80M (+1044.2%) for the fiscal year ending Dec 2026, a step up from the -23.8% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$2.22M-6.5% QoQ
Last fiscal yearDec 2025
-$8.47M-23.8% YoY
LTMMar 2026
-$8.18M+33.3% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-11.6%+1129.5%+1141.1 pp
1 year-23.8%+1044.2%+1068.1 pp
3-year CAGR-38.4%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(8.47M) USD
Year-over-year change
+23.8%
Reported Analyst consensus estimate

Net Income vs competitors

How BYSI compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +33.3% is the 4th highest of 9, against a peer median of +15.8%.
  • Over three fiscal years its annual growth of -38.4% compares with a peer median of +13.7%.
BYSI Competitors
Net Income for BYSI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GUTSFractyl Health, Inc. Common StockLTM Mar 2026$108M USD+21.2%+44.8%—
ALXOALX Oncology Holdings Inc.LTM Mar 2026$88.87M USD-31.7%-6.3%—
CAMPCAMP4 Therapeutics CorporationLTM Mar 2026$86.3M USD+66.7%—2193.7%
ATYRaTyr Pharma, Inc.LTM Mar 2026$70.03M USD+10.4%+17.8%36859.5%
BMEABiomea Fusion, Inc.LTM Mar 2026$44.95M USD-65.1%-8.9%—
DTILPrecision BioSciences, Inc.LTM Mar 2026$43.6M USD+98.3%-25.7%96.7%
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026$39.95M USD+162.9%+13.7%—
HYFTMindWalk Holdings Corp.LTM Jan 2026CA$12.18M CAD-73.6%+21.9%66.4%
BYSIBeyondSpring Inc.LTM Mar 2026$8.18M USD+33.3%-38.4%—
Peer median (excluding BYSI) —+15.8%+13.7%1145.2%

Competitors are the stored peer set for BYSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(68.21M)(36.28M)(21.03M)(11.12M)(8.47M)
Depreciation & Amortization61K232K302K285K87K
Deferred Income Tax(1.2M)0000
Stock-Based Compensation3.15M1.67M554K2.06M0
Change in Working Capital18.41M6.41M2.71M(1.38M)(376K)
Accounts Receivables(1.77M)0000
Inventory1.77M0186K(19K)(18K)
Accounts Payables(560K)(575K)00(76K)
Other Working Capital18.97M6.98M2.52M(1.36M)(282K)
Other Non-Cash Items546K(178K)988K(6.29M)(11.26M)
Operating Cash Flow(47.24M)(28.15M)(16.47M)(16.44M)(20.02M)
Capital Expenditures(2.84M)(34K)(100K)(224K)(50K)
Acquisitions (Net)20.41M00010.05M
Purchases of Investments(44.23M)(32.2M)00(14.95M)
Sales of Investments26.66M49.76M0018.43M
Other Investing Activities(20.41M)717K0(11.79M)0
Investing Cash Flow(20.41M)18.25M(100K)(12.01M)13.48M
Debt Repayment0(1.57M)03.91M286K
Common Stock Issued39K0001.99M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(38K)5M4K22.87M0
Financing Cash Flow1K3.43M4K26.79M2.27M
Effect of Forex Changes(258K)(756K)(76K)(33K)9.13M
Net Change in Cash(67.91M)(7.23M)(16.65M)(1.7M)4.86M
Free Cash Flow(50.09M)(28.19M)(16.57M)(16.67M)(20.07M)

BeyondSpring Inc.

NASDAQ:BYSI

Intrinsic Alpha fair value

Locked

Current Price

$1.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.